Duke University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).
Duke University: 1,725 sponsored US clinical trials, 187 recruiting.
Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,725 total, page 34 of 35
Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer
NCT00057915
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
NCT00227370
Comparison of Two Programs to Improve Blood Pressure Treatment Adherence
NCT00123058
Testing Pharmacological Therapies for Pregnant Smokers
NCT00224419
Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity
NCT00402480
Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure
NCT00047437
Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression
NCT00340379
Computer Program in Improving Communication Between Doctors and Patients With Stage IV Cancer
NCT00276627
Coping Skills Training for Early Rheumatoid Arthritis
NCT00056394
Telephone Enhancement Procedure for Continuing Care - 1
NCT00067171
Partner-Assisted Emotional Disclosure for GI Cancer
NCT00734513
Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer
NCT00049309
Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases
NCT00849745
Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy
NCT00215163
Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
NCT00613093
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
NCT00829179
Diet and Exercise-Based Counseling Program Compared With a Standard Counseling Program in Patients With Early-Stage Prostate Cancer
NCT00044980
Magnetic Resonance Imaging of Atrial Septal Defects
NCT00498446
Project CHEER (Comprehensive Headache Evaluation, Education, Relief)
NCT00417742
EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
NCT00041028
Study of Health Promotion in Patients With Early-Stage Breast or Prostate Cancer
NCT00037024
Hydroxyurea in Young Children With Sickle Cell Anemia
NCT00519701
Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
NCT00023595
Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome
NCT00610610
Clinical Outcomes and Cost of Gram Negative Bacteremia
NCT02599220
Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)
NCT00610909
Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer
NCT00312429
Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery
NCT00041392
Combined Behavioral/Pharmacological Therapy for Insomnia
NCT00044629
Effect of Brain Lesion Severity on Treatment Response in Late-Life Depression
NCT00339066
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
NCT00016991
Amphetamine-Enhanced Stroke Recovery
NCT01905371
Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma
NCT00006474
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00010127
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
NCT00005951
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors
NCT00005955
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
NCT00005081
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
NCT00005952
Temozolomide in Treating Patients With Brain Metastases
NCT00005954
Comparison of Barium Enema, Computed Tomographic Colonography, and Colonoscopy in Detecting Colon Cancer
NCT00016029
Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
NCT00005816
Biological Therapy in Treating Patients With Advanced Cancer
NCT00005956
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC
NCT00134680
Exercise Training Versus Drug Therapy for Treating Depression in Older Adults
NCT00331305
Behavioral Insomnia Therapy for Fibromyalgia
NCT00000397
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00004211
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
NCT00003463
Flt3L in Treating Patients With Metastatic Colorectal Cancer
NCT00003431
Immunotherapy in Treating Patients With Metastatic Breast Cancer
NCT00003432
Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer
NCT00003434
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 136 |
| Phase 2 | 175 |
| Phase 3 | 41 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Duke University pipeline
187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).
Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Duke University: open-pipeline peers nationwide
Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,725 trials (± recruiting share)
- University of California, San Francisco · 1,713 trials · 16% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Carnegie Mellon University · 11% recruiting · 37 trials
- CAMC Health System · 11% recruiting · 28 trials
- UConn Health · 11% recruiting · 178 trials
- Hartford Hospital · 11% recruiting · 75 trials
Related
What to do with this Duke University page
1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.
- 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.